GNLX: Genelux Corporation Stock

by  •  • Comments Off on GNLX: Genelux Corporation Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 92.68
Enterprise Value ($M) 76.47
Book Value ($M) 29.85
Book Value / Share 0.80
Price / Book 3.11
NCAV ($M) 26.81
NCAV / Share 0.72
Price / NCAV 3.46

Profitability (mra)
Return on Invested Capital (ROIC) -0.93
Return on Assets (ROA) -1.20
Return on Equity (ROE) -1.96

Liquidity (mrq)
Quick Ratio 4.67
Current Ratio 4.67

Balance Sheet (mrq) ($M)
Current Assets 35.95
Assets 38.98
Liabilities 9.14
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.01
Operating Income -31.70
Net Income -29.87

Cash Flow Statement (mra) ($M)
Cash From Operations -21.23
Cash from Investing -8.13
Cash from Financing 28.51

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
10-25 13G Highbridge Capital Management Llc 6.80
10-22 13G/A Szalay Aladar 9.90 -18.44

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-05-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO
2025-04-29 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1)
2025-03-28 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2024-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-05-13 75,785 315,092 24.05
2025-05-12 181,934 487,437 37.32
2025-05-09 40,622 104,645 38.82
2025-05-08 141,631 554,762 25.53

(click for more detail)

Similar Companies
GLSI – Greenwich LifeSciences, Inc. GLTO – Galecto, Inc.
GLYC – GlycoMimetics, Inc. GNPX – Genprex, Inc.
GOVX – GeoVax Labs, Inc.


Financial data and stock pages provided by
Fintel.io